Transparency Market Research Reports incorporated a definite business overview and investigation inclines on “Rubella Diagnostic Testing Market”. This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Rubella or German measles is a contagious and acute viral infection caused by the rubella virus. Generally, rubella infection occurs most often in young adults and children. While the rubella infection is typically mild in children, this disease has serious consequences in pregnant women causing congenital defects and fetal death.
Browse Full Report with TOC: http://www.transparencymarketresearch.com/rubella-diagnostic-testing-market.html
Some of the diagnostic testing techniques usually adopted for the diagnosis of rubella are as follows:
- Clinical evaluation
- Serological testing
- Monoclonal antibodies
- Latex slide agglutination test
- Flow cytometry
At present, there is no standard drug therapy available for treating rubella. However, MMR vaccine, which is an immunization vaccine, is administered to children for protecting against measles, mumps, and rubella. The goals of medications given to the patients are only to prevent complications and to reduce morbidity.
In terms of geography, Europe is the leading market in rubella diagnostic testing market due to the high susceptibility to rubella. It has been stated that, as of 2004, the U.S. was declared free of rubella and the transmission of the rubella virus was halted across the regions of the Americas in 2009. Furthermore, on January 2014, the PAHO (Pan American Health Organization) and WHO (World Health Organization) declared the Latin American country, Colombia free of rubella. However, it has been observed, epidemics of rubella still occur in developing regions such as South East Asia and Africa, where the vaccine for rubella is not available or accessible. The countries with the largest number of cases in 2012 were Syria, Tajikistan, Macedonia, Timor-Leste and Thailand.
Some of the primary factors driving the growth of rubella diagnostic testing market are low awareness rate among population and introduction of advance point of care diagnostic technologies. For instance, Bio-Rad Laboratories, Inc., a global company engaged in the development and commercialization of clinical diagnostic and life science research products introduced BioPlex 2200 MMRV (Measles, Mumps, Rubella, and Varicella-Zoster Virus) IgG kit for better diagnosis and prevention of these diseases. This kit is designed to provide simultaneous results for the four diseases i.e. Measles, Mumps, Rubella, and Varicella-Zoster Virus (chicken pox). Thus, the introduction of promising point of care diagnostic kits in this market is likely to boosts the overall rubella diagnostic testing market due to the high success and effectiveness rate of the potential molecules. Furthermore, increasing government support for developing novel therapies and vaccines; along with high research and development initiatives on the development of advance diagnostic techniques are expected to fuel the growth of this market. In addition, technological breakthrough such as microfluidic point of care diagnostic kits and increased focus on retaining superior quality of life are some of the factors that might contribute to the growth of this market. However, rise in overall healthcare expenditure and product availability are some of the market-restraining factors that might hinder the growth of the rubella diagnostic testing market in the near future.
At present, the rubella diagnostic testing market is an burgeoning market venture; specifically in regions such as Africa and South East Asia due to the low rate of vaccine coverage in these regions. However, at present this market is highly fragmented owing to the involvement of many established and emerging players. Some of the key players engaged in this market are Abbott Laboratories, Beckman Coulter Inc., bioMérieux SA, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Ortho Clinical Diagnostics and Siemens AG, amongst others.
Read More Reports on Medical Devices Markets: http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Enquiry before Buying @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2935
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
Followed LinkedIn :-https://www.linkedin.com/today/post/article/20140808045047-349336221-rubella-diagnostic-testing-market-2014-2020
Transparency Market Research
90 State Street,
NY — 12207
USA — Canada Toll Free 866-552-3453
Browse Market Research Blogs: